INTRODUCTION
============

Lung cancer is the most common malignancy worldwide, accounting for 13% of all new cancer cases.[@B1] According to the Global Burden of Disease Study 2015, lung cancer is also the leading cause of cancer mortality-over 1.7 to 1.8 million deaths every year and the highest age-standardized death rate (26.6 deaths per 100,000 population) among cancers.[@B2] In Brazil, the *Instituto Nacional de Câncer* (INCA, Brazilian National Cancer Institute) estimated a total of 596,000 new cancer cases in 2016, 28,220 (4.7%) of which were primary lung malignancies.[@B3] Lung cancer is the second most incident cancer among men and the fourth most incident cancer among women in the country ([Figure 1](#f1){ref-type="fig"}).[@B3]

Figure 1Brazilian National Cancer Institute estimate for new cancer cases in 2016 by gender. Adapted from Instituto Nacional de Câncer José Alencar Gomes da Silva.[@B3]

As in most countries, lung cancer is the major cause of cancer mortality in Brazil. The age-standardized 5-year survival rate in the country is 18%, which is concordant with global rates, ranging from 10% to 20%.[@B4] Lung cancer age-standardized mortality rates in 2012 were 16.5 deaths/100,000 population and 8.6 deaths/100,000 population in men and women, respectively.[@B5] In Brazil, mortality increased from 10.6 deaths/100,000 population to 31.1 deaths/100,000 population in men and from 3.0 deaths/100,000 population to 5.4 deaths/100,000 population in women from 1979 to 2004.[@B6] Mortality rates (both crude and age-adjusted) among men and women differed in magnitude in all periods (1980-2007), with a more significant relative increase among females than among males (78.4% vs. 8.2%), which was probably related to differences in smoking prevalence ([Figure 2](#f2){ref-type="fig"}). Moreover, age-specific mortality rates increased among men aged 65 years or older and among women across all age groups.[@B7]

Figure 2Crude and age-adjusted lung cancer mortality rates by gender. Brazil, 1980-2007.[@B7]

The Brazilian health care system is divided into private and public coverage (27% and 73%, respectively).[@B8] As will be discussed later in the present analysis, significant discrepancies in the availability of health care resources and patient outcomes are evident between these two different settings.

RISK FACTORS AND TOBACCO EXPOSURE
=================================

Trends in lung cancer mortality in Brazil reflect the epidemiological model of tobacco-related mortality. Tobacco use increased during the 1950s and the 1960s, peaking in the 1970s. Notably, strong public health policies in Brazil have led to a subsequent reduction in tobacco consumption, which may serve as an example for other low- and middle-income countries. Brazilian national studies indicate that smoking prevalence has diminished approximately 50%, as have tobacco-related deaths.[@B9] Data from a nationwide surveillance study of risk factors and protective factors for chronic diseases carried out by telephone inquiries showed that 12,7% of men and 8.0% of women aged 18 years or older were smokers in 2016[@B10]; those proportions were 43.3% and 27.0% in 1989, respectively.[@B11]

The major components of Brazilian anti-tobacco policies include prohibition of smoking in public places, higher taxes for tobacco products, and health-warning labels on cigarette packages. Despite this decline in tobacco consumption, national surveys involving children in Brazil still show a significant prevalence of smokers among the young population in various cities.[@B12] Moreover, smoking-related illnesses remain a major economic health burden. It has been estimated that, by 2020, the population-attributable fraction of the lung cancer burden associated with smoking in Brazil will be 83.3% among men and 64.8% among women.[@B13] ^)^ These data are relevant to reinforce the role of local tobacco control. Data on the prevalence of lung cancer related to other risk factors, such as asbestos exposure, residential wood smoke exposure, and radon exposure, are lacking.

DIAGNOSIS AND STAGING
=====================

Data on how lung cancer is diagnosed and staged are relatively scarce in Brazil; however, some datasets have been published in the past 15 years. Similarly to what occurs in developed countries, non-small cell lung cancer (NSCLC) is usually diagnosed in advanced stages and has poor survival rates in Brazil. Overall, approximately 70% of the patients present with either locally advanced or metastatic disease (stages III and IV, respectively). According to a large cancer registry database in the state of São Paulo, Brazil, only 8.8% of the 20,850 lung cancer patients registered in the system between 2000 and 2010 had stage I disease.[@B14] These proportions are in contrast with the higher frequencies of 15.4% and 14.5% reported for a similar period in the USA and in the United Kingdom, respectively.[@B15] ^,^ [@B16] A Brazilian lung cancer screening trial was conducted in order to address the effectiveness of screening in the country.[@B17] Between January of 2013 and July of 2014, 790 participants volunteered to participate, following the same eligibility criteria applied in a USA national lung screening trial. NSCLC was diagnosed in 10 participants (prevalence of 1.3%), most of whom were classified as stage I.[@B17]

Several retrospective series have been published reporting single institution data on lung cancer histology, staging, and outcomes ([Table 1](#t1){ref-type="table"}).[@B18] ^-^ [@B26] Interestingly, it seems that squamous cell histology is more prevalent in public health care services, whereas adenocarcinoma predominates in private institutions. In the USA, squamous cell carcinoma and small cell lung carcinoma (SCLC) rates declined after the 1990s, and adenocarcinoma rates rose in the period between 2006 and 2010 among every racial/ethnic/sex group.[@B27] A major cancer center in the state of São Paulo reviewed data collected between 1997 and 2008 from 1,887 lung cancer patients.[@B18] A decline in the proportion of SCLC was reported in two different time periods (1997-2002 and 2003-2008), although no significant changes occurred in the NSCLC histological subgroups.[@B18] However, in an epidemiological study evaluating case registry data from 35,018 patients diagnosed with NSCLC in the states of Rio de Janeiro and São Paulo between 2000 and 2011, a shift was observed towards a prevalence of adenocarcinoma histology over squamous cell carcinoma (43.3% vs. 36.5%) in recent years.[@B28]

Table 1Lung cancer distribution by histology and staging.AuthorNType of facilityNSCLC, %SCC/Ad ratioIII-IV, %Ismael et al.^(^ [@B18] ^)^1,887Public890.9371Younes et al.^(^ [@B19] ^)^737Public100^a^1.2074Westphal et al.^(^ [@B20] ^)^352Public912.5466Barros et al.^(^ [@B21] ^)^263Public871.9694Novaes et al.^(^ [@B22] ^)^240Public801.2572Araujo et al.^(^ [@B23] ^)^566Private100^a^0.3380Caires-Lima et al.^(^ [@B26] ^)^232Public920.4893Mascarenhas et al.^(^ [@B24] ^)^338Private830.3878Freitas et al.^(^ [@B25] ^)^93Private100^a^0.3388[^1]

DIAGNOSTIC PROCEDURES
=====================

Delay in the diagnosis of cancer in general and of lung cancer in particular is one of the major challenges faced in Brazil. Information on the timeframe for an individual with suspicious symptoms to receive a diagnosis of lung cancer, to visit a tertiary health care facility, and to initiate therapy is lacking. Nonetheless, the high rate of late-stage diagnoses, the low frequency of patients receiving curative-intent therapy, and the large number of patients not receiving any disease-directed treatment reflect a significant delay and inefficiency in the diagnostic workflow, at least in the public health care scenario.[@B21] ^,^ [@B29] In general, access to diagnostic imaging is limited in many regions. A retrospective study from two institutions showed that 89% of the patients were diagnosed with cancer via chest X-ray, whereas only 20% were diagnosed via CT.[@B21] Moreover, access to invasive diagnostic procedures is limited, with few facilities performing bronchoscopy or transthoracic biopsies.

In a 2005 survey, the rate of CT scanners per one million population was 4.9 and 30.8 in the public and private health care settings in Brazil, respectively.[@B30] These rates underscore the difficulties in the access to adequate diagnostic evaluation in the public health care system, whereas the rates described in private health care facilities are similar to those in developed countries, such as the USA and Japan (31.5 and 32.2, respectively). There is also a geographic disproportion of technology distribution, with higher numbers of diagnostic facilities in the southeast and south regions and lower numbers in the north and northeast regions.[@B30] In 2010, the agency that regulates the private medical sector-*Agência Nacional de Saúde Suplementar* (National Health Insurance Agency)-approved the use of positron emission tomography (PET) for lung cancer staging; however, the public health care system-*Sistema Único de Saúde* (Brazilian Unified Health Care System)-incorporated the technology only in 2014. The number of facilities providing PET has increased sharply in the country, reaching 124 scanners and 15 cyclotrons in 2014, distributed in 21 of the 26 states of Brazil and the Federal District of Brasília (personal communication). The lower availability of the technology in the public health care system is noteworthy.

Reports on the Brazilian experience with invasive diagnostic procedures are also scarce or outdated. The *Sociedade Brasileira de Pneumologia e Tisiologia* mailed 576 questionnaires to physicians-mostly pulmonologists-addressing their experience with bronchoscopy.[@B31] Of the respondents, 111 (19.2%) declared being familiar with both flexible and rigid bronchoscopy, the majority of those (n = 63; 56.7%) performing at least 100 fiberoptic bronchoscopies per year, which is in line with international recommendations.[@B32] ^,^ [@B33] In 2007, experts at INCA reported their experience with bronchoscopy-guided transbronchial needle aspiration, which is considered a safe and effective procedure.[@B34] Samples were deemed satisfactory in 57% of the cases, 81% of those allowing a definitive diagnosis.[@B34] Some groups have also developed expertise in CT-guided transthoracic fine-needle aspiration, showing high diagnostic yield, accuracy, and safety.[@B35] After 2010, endobronchial ultrasound was introduced in a few large institutions, and the initial experience with 50 cases has been reported.[@B36] ^,^ [@B37] In most cases, endobronchial ultrasound was recommended for diagnostic purposes (76%), yielding adequate specimens in 74% of the cases.[@B36] In general, these data suggest that referral centers have adequate expertise, but it is unknown what proportion of patients has access to these.

MOLECULAR TESTING
=================

The introduction of molecular testing in lung cancer is key to improving therapeutic results. Unfortunately, access, affordability, and incorporation strategies remain significant challenges in low- and middle-income countries.[@B38] Access to molecular testing is limited in Brazil, and data on the frequency of clinically useful mutations is still scarce, especially in the public health care system. Unpublished information (personal communication) on approximately 1,700 cases obtained from a marketing survey conducted in the first half of 2014, suggests that, overall, fewer than half of the patients are tested for *EGFR* mutations in Brazil. Approximately two thirds of the tests are performed in the private sector, and only one third is performed in public health care institutions. These rates are likely to be lower for anaplastic lymphoma kinase (*ALK*) gene testing.[@B39] The major issues regarding molecular genotyping are as follows: 1) reimbursement and logistics; 2) access to targeted therapy; 3) patient and medical information (i.e., unawareness); and 4) limited laboratory infrastructure for molecular testing (restricted to a few large centers or cities). Pharmaceutical companies involved in distributing EGFR tyrosine kinase inhibitors (TKIs) have provided most of the molecular testing that has been performed in the past few years. Regulatory agencies have recently approved *EGFR* testing and the reimbursement of its costs by private health insurance companies. The development of local guidelines, the definition of test algorithms, and the application of comprehensive policies that associate testing with personalized treatment are essential to enable a functional process to make targeted therapy a reality for a larger proportion of patients.[@B39]

Some efforts have been made to compile data on the frequency of molecular abnormalities in Brazilian patients ([Table 2](#t2){ref-type="table"}).[@B40] ^-^ [@B48] Overall, the data suggest that the frequency of *EGFR* mutations is lower in Brazil (approximately 25%) than in Asia but higher than in White populations in North America and Europe ([Figure 3](#f3){ref-type="fig"}), confirming findings from other Latin American countries.[@B49] It has been speculated that the ethnic background could be responsible for the distinct molecular profile seen in these instances, perhaps due to the characteristic genetic admixture seen in Brazilians, inherited from European, African, and Native American ancestors. The frequency of *ALK* translocations has been reported to range from 3% to 4%.[@B48] ^,^ [@B50] ^,^ [@B51] To explore these points in a better way, two multicenter studies have been initiated, led by the Brazilian National Clinical Cancer Research Network and the Latin American Cooperative Oncology Group. These consortiums are supported by pharmaceutical companies, as well as by North American societies, such as the American Society of Clinical Oncology and the American Association for Cancer Research.

Table 2Frequency of *EGFR* mutations and clinical characteristics in Brazilian cohorts.AuthorNEGFR mutation, %NS, %Female, %non-SCC, %SettingPontes et al.^(^ [@B40] ^)^3,37125NR58100ClinicalYen et al.^(^ [@B45] ^)^417253457100ClinicalSaito et al.^(^ [@B46] ^)^39526275191ClinicalDomingues et al.^(^ [@B43] ^)^28827265695ClinicalBacchi et al.^(^ [@B41] ^)^20730545882ClinicalGomes et al.^(^ [@B48] ^)^162333248100ClinicalMelo et al.^(^ [@B42] ^)^15722154768ResearchDe Sa et al.^(^ [@B44] ^)^10028NRNR100Clinical[^2]

Figure 3Prevalence of *EGFR* mutations around the world. *EGFR* mutations are in general more prevalent in Asian countries, whereas Latin American countries tend to have an intermediate prevalence between Asia and Europe/North-America. NR: not reported. Adapted from Werustky et al.[@B49]

TREATMENT
=========

*Surgery*
---------

Precise data on the number of surgical procedures performed to treat lung cancer are unavailable. According to the Brazilian Technology Information Department of the SUS-a public health care system database that covers approximately 75% of the Brazilian population-a median of 964 pulmonary lobectomies and segmentectomies were performed yearly between 2007 and 2014.[@B52] However, this number has some potential flaws, though, since lobectomies and segmentectomies could have been performed for diseases other than lung cancer; the database is restricted to the public health care system, and the quality of the data is questionable.

Only a limited proportion of patients undergo curative-intent surgery. Data suggest that approximately 25% of the patients undergo surgical treatment.[@B19] ^,^ [@B22] ^,^ [@B23] Access to curative surgery is likely influenced by socioeconomic differences, performance status scores, presence of comorbidities, advanced age, and geographic distribution.[@B22] According to the São Paulo State Department of Health, patients with a lower educational level are less likely to undergo surgery.[@B14] Currently, there are 763 thoracic surgeons in Brazil, concentrated in the south and southeast regions of the country.[@B53] In a survey promoted by the *Sociedade Brasileira de Cirurgia Torácica* (Brazilian Society of Thoracic Surgery), 51% of the respondents stated that they worked in cities with more than one million inhabitants.[@B54] Therefore, although the absolute number of thoracic surgeons is adequate, their distribution is a cause for concern. Medium-sized cities and highly populated regions in central, northern, and northeastern Brazil are underserved in terms of thoracic surgery.

Video-assisted thoracic surgery is rapidly growing in the country. The 30-day mortality rates in the two largest surgical case series reported, which included patients who underwent lobectomy due to lung cancer, were 2.9% and 4.3%.[@B55] ^,^ [@B56] Large international case series published in the 2000s showed a somewhat lower mortality rate (of approximately 1%).[@B57] These numbers suggest that there is room for improvement in lung cancer surgery in Brazil. The dissemination and availability of new techniques, such as video-assisted and robotic surgery, will hopefully speed up this process.

*Radiation therapy*
-------------------

According to the *Comissão Nacional de Energia Nuclear* (Brazilian National Commission of Nuclear Energy), there 224 radiation therapy (RT) facilities (65% of which are public) are currently available in Brazil, but they are unequally distributed across the country (2 of the 26 states lack RT facilities).[@B58] These facilities have approximately 250 linear accelerators that can provide treatment for more than 150,000 cancer patients per year. The World Health Organization recommends one megavoltage machine for every 600,000 inhabitants in order to provide adequate treatment availability. With an estimated population of 200 million inhabitants, Brazil needs approximately 335 megavoltage machines. This corresponds to a deficiency of nearly 100 RT devices to provide full treatment coverage for approximately 100,000 untreated patients per year.[@B59]

Approximately 550 radiation oncologists work in Brazil, mostly in the southeastern region, where the majority of the linear accelerators (124/235 units; 52.7%) are centralized.[@B60] There are long waiting lists to start treatment (mean waiting time, 113 days) mainly in public health care centers, with a potential impact on patient outcome. In order to minimize this problem, the government has implemented different strategies.[@B60] The most recent and outstanding one was the acquisition of 80 linear accelerators that are able to deliver high-quality therapy, including three-dimensional conformal RT and potential for upgrades to deliver intensity-modulated RT. At the same time, 39 of the already existing RT facilities are intended to be expanded, and 41 RT facilities are to be created, the federal government investing more than 250 million US dollars. As a result, it is expected that all geographic areas in the country should be properly served in the near future, avoiding patient migration for treatment. Nevertheless, the backlog of patients requiring therapy and the need to train qualified human resources remain as critical challenges in need of urgent measures.

According to a survey sent to all RT services registered with the *Sociedade Brasileira de Radioterapia* (Brazilian Society of Radiotherapy), approximately 25% of all RT procedures are performed in lung cancer patients. Among these, approximately half are submitted to palliative treatment only, and very few are in early stages (I or II). Few centers have stereotactic body RT or stereotactic ablative RT to treat localized disease, only one of them providing care via the public health care system. Among the 13 centers that provide this technology, only 10 use it for lung cancer treatment. The preliminary experience (21 patients; mean age, 81 years) with stereotactic body RT in a private health care institution showed that the treatment was mostly recommended for elderly or clinically inoperable patients. With a median follow-up period of 12 months, local control was achieved in 95% of the patients, and the complication rate was very low.[@B61]

There is a lack of well-annotated outcome data on locally advanced NSCLC in Brazil. Although chemoradiation therapy is the standard of care in most facilities, treatment protocols are quite diverse. For instance, in a retrospective analysis of 171 elderly patients with unresectable, locally advanced NSCLC, the treatment offered was best supportive care, in 39%; definitive RT alone (at least 40 Gy), in 32%; and combined chemoradiation therapy, in only 29%.[@B62] In order to improve the description of the results regarding this issue in Brazil, the Latin American Cooperative Oncology Group and the *Grupo Brasileiro de Oncologia Torácica* are coordinating a multicenter study to collect data on locally advanced NSCLC from 7 referral centers for cancer in the country.

The Brazilian experience with palliative RT demonstrates high rates of symptom control (70-84%) and a median overall survival (OS) of approximately 3 months following hypofractionated regimens.[@B63] ^,^ [@B64] Regimens based on fewer RT fractions can be very convenient in centers with long waiting lines. High dose-rate brachytherapy is also available in approximately half of the centers*,* although reimbursement in public health care services is limited to gynecological cancers.[@B65] The endobronchial procedure is used mostly for palliative purposes and in very few centers (11/59 surveyed), only 1 belonging to the public health care system. The overall symptom relief rate was 70% in a national case series involving 78 patients.[@B66]

*Systemic therapy*
------------------

In comparison with developed countries, the incorporation of systemic therapies and technologies for lung cancer diagnosis and treatment suffers from significant delays in Brazil. More importantly, inequities in the access to drugs and molecular testing between public and private health care systems are striking. For instance, standard third-generation chemotherapy agents, such as taxanes and gemcitabine, were only incorporated into the public health care system in the late 2000s, and pemetrexed is still unavailable. Targeted therapies, such as monoclonal antibodies (bevacizumab) and first-generation EGFR TKIs, are available only for patients with private health care coverage. Although EGFR TKIs were included in the public health care system in 2015, both mutation testing and medications are neither adequately available nor routinely provided to patients yet. The first ALK inhibitor approved for use in Brazil was crizotinib in February of 2016, whereas ceritinib is still being evaluated. The delay in the approval of crizotinib was estimated to result in over 700 patients dying prematurely from their disease as a consequence of the lack of access to this effective agent.[@B67]

In a large retrospective review, Younes et al. collected data from 2,673 metastatic NSCLC patients treated in two cancer centers in the city of São Paulo between 1990 and 2008.[@B68] Notably, 49% of the patients had a Karnofsky performance status of 70% or less, reflecting the late access of the patients to specialized cancer centers. The majority (57.9%) of the patients were treated with first-line chemotherapy, whereas second- and third-line chemotherapy was offered to 23.4% and 8.0% of the patients, respectively. A platinum-based regimen as the first-line treatment was used in 61% of the patients (median OS, 8.0 months).[@B68] Naime et al. reviewed the heterogeneity of systemic regimens employed in a cohort of 564 metastatic NSCLC patients, also in the city of São Paulo, between 1990 and 2003.[@B69] Again, 47% of the patients had an Eastern Cooperative Oncology Group performance status scale score of 2-3; chemotherapy was used in 59% of the patients, 47 different regimens being used. Although most (83.5%) of the patients received a platinum salt, only 57.3% were treated with a platinum doublet regimen. Taxanes and gemcitabine were offered to only 19.0% and 15.8% of patients, respectively. The median OS was 8.3 months.[@B69] Araujo et al. reported the results of palliative chemotherapy given to 339 NSCLC patients treated in a private health care institution in the city of Rio de Janeiro between 1998 and 2010.[@B23] Most patients received a first-line platinum-based regimen, its combination with paclitaxel being the most common, in 31%; followed by pemetrexed, in 21%; and gemcitabine, in 17%. The median OS was 12.2 months.[@B23] These and other studies are summarized in [Table 3](#t3){ref-type="table"}.

Table 3Summary of the most relevant studies on non-small cell lung cancer palliative systemic treatment in Brazil.AuthorDesignNStudy periodPS ≥ 2, %Type of facilitymOS, monthsChemotherapyYounes et al.^(^ [@B68] ^)^Re2,6731990-200849^a^Private8.0Naime et al.^(^ [@B69] ^)^Re5641990-200347Private8.3Araujo et al.^(^ [@B23] ^)^Re3391998-201011Private12.2Leite et al.^(^ [@B75] ^)^Re1632006-2013NAPublicNAZukin et al.^(^ [@B70] ^)^Pro2052008-2011100Public5.3/9.3^b^Pereira et al.^(^ [@B76] ^)^Re822007-2011NAPrivate26.4/16.4^c^Jardim et al.^(^ [@B77] ^)^Re562006-20117.2Private14.8Pereira et al.^(^ [@B71] ^)^Pro441996-199850^a^Public7.5^d^EGFR TKICaires-Lima et al.^(^ [@B72] ^)^Re492010-2013NAPublicNR^e^Domingues et al.^(^ [@B43] ^)^Re322011-2014NAPublic62.9Freitas et al.^(^ [@B73] ^)^Re612010-2014NAPrivate36.3/NR^f^[^3][^4]

Given the relatively high rate of patients being diagnosed late and having advanced disease and poor performance status, Brazilian investigators established a national research infrastructure to explore the best approach to manage fragile patients. In a multi-institutional phase III trial, Zukin et al. compared a carboplatin plus pemetrexed regimen with the use of pemetrexed alone in 205 metastatic NSCLC patients with a performance status of 2.[@B70] Notably, the authors confirmed the benefit of the platinum-doublet regimen, showing improved overall response rate, progression-free survival, and OS in the group receiving the combined therapy. In parallel, Pereira et al. demonstrated the feasibility of a cisplatin plus vinorelbine regimen for elderly patients with NSCLC in a prospective phase II trial.[@B71]

Several groups have reported their experience with targeted therapies in Brazil, especially regarding their local experience with EGFR TKIs. Caires-Lima et al. reported the efficacy and safety of erlotinib in patients with advanced adenocarcinoma harboring sensitizing *EGFR* mutation.[@B72] In that single-center experience in the city of São Paulo, 49 consecutive cases treated between 2010 and 2013 were evaluated; of those, 22% were treated with a first-line regimen, and 63% and 14% were treated with second-line and third-line regimens, respectively. Treatment was well tolerated and led to a clinical benefit rate of 64%. One-year OS rate was 94%, and the median survival had not been reached at the time of publication.[@B72] Domingues et al. described the outcomes of 32 *EGFR* mutant cases treated with EGFR TKIs in the city of Rio de Janeiro.[@B43] The median OS was an impressive 62.9 months.[@B43] Freitas et al. reported the outcomes of 61 patients treated with a TKI (from a cohort of 115 metastatic NSCLC patients with an *EGFR* mutation) in another cancer institution in the city of São Paulo between 2010 and 2014.[@B73] The median progression-free survival was 13.9 months and 11.4 months in the patients using first-line and the second-line regimens, respectively. The median OS was not different between those two groups (36.3 months vs. not reached; p = 0.61).[@B73] These data confirm the benefit of selecting patients locally and reinforce the importance of correct identification of *EGFR* mutant cases for targeted therapy.

Given that these medications have only recently been approved, there is still no information regarding the use of immunotherapy in the country.

CLINICAL RESEARCH AS AN OPPORTUNITY
===================================

The participation of patients in international, industry-sponsored clinical trials has been significant in various academic institutions in Brazil and has facilitated access to novel therapies. For instance, Zylberberg et al. reported the experience involving 97 consecutive patients with advanced NSCLC enrolled in clinical trials at INCA.[@B74] Half of the patients were initially enrolled in a first-line regimen trial; of those patients, 31% also participated in a subsequent trial using a second-line regimen or a later-line regimen. Notably, all patients eventually received a contemporary standard treatment, as follows: taxanes, in 49% of the patients; pemetrexed, in 30%; gemcitabine, in 31%; and TKIs, in 37%. This highly selected group had a median OS of 17.2 months, which is higher than are the historical data outside of a clinical trial.[@B74] As more trials are open nationally, the participation of community-based institutions tends to increase, making research an option for more patients. Clinical research in Brazil faces a number of challenges, including the slow and lengthy regulatory process that reduces and significantly limits the opportunities to participate in clinical trials. The mean time for regulatory approval of a research protocol in Brazil is three times longer than that in the USA and other leading countries in research, having an impact on the availability of studies and reducing the timeframe for patient accrual.

PERSPECTIVES
============

Investing in epidemiological research and evidence-based lung cancer care should be a strategic priority for the Brazilian health care system. Important steps have been undertaken to improve case registry data; however, those available still cover only a small proportion of the population, and the quality of data collection is often questionable. Lung cancer control certainly faces significant challenges in Brazil ([Chart 1](#t4){ref-type="table"}). Collecting high-quality data on epidemiology and health economy will help understand the current scenario and will contribute to the process of defining strategic plans. Promising examples include local studies showing favorable cost-effectiveness ratios that support the incorporation of PET-CT for lung cancer staging in the public health care system, as well as chemotherapy doublets in the first-line treatment of metastatic NSCLC patients with a performance status of 2. Bringing together community representatives, health care providers, pharmaceutical companies, tax payers, researchers, and government officials is an important strategy to enable the definition and implementation of programs that will have impact on the areas of prevention, diagnosis, and access to standard therapies. The participation of oncology societies and workgroups will be key to orchestrating such efforts. These strategies should involve international collaboration and strongly focus on decreasing health care discrepancies.

Chart 1Summary of the current scenario and proposed actions to improve lung cancer control in Brazil.Current scenarioActionLung cancer is a leading cause of cancer death in Brazil.\
Smoking-related lung cancer remains a major health burden.\
Data on lung cancer diagnosis, staging, therapy, and outcomes are scarce.\
There is a deficiency in radiation therapy machines to provide full treatment coverage in the country.\
There is a significant delay in the approval of systemic therapies by local regulatory agencies.\
Inequities in the access to diagnosis, therapy, and molecular testing between public and private health care systems are remarkable.\
A lengthy clinical research approval process limits access to clinical trial opportunities.Reinforce the role of tobacco control, and stimulate programs directed to the entire population, particularly teenagers.\
Collect high-quality data on epidemiology and health economy aiming at describing diagnosis, staging, access to therapy, and outcomes.\
Strengthen, bring together, and stimulate productive dialogue among medical societies, advocacy groups, government, pharmaceutical companies, and regulatory agencies.\
Propose and implement programs to positively impact on prevention, diagnosis, and access to therapy.\
Increase local funding for lung cancer prevention, diagnosis, and treatment research.\
Stimulate the development of research units and participation in clinical trials.\
Stimulate and implement international collaborations.

FINAL CONSIDERATIONS
====================

This comprehensive review addresses the current landscape and emphasizes various weaknesses in the management of lung cancer in Brazil. Specific data are often scarce or absent in various instances, which should motivate concentrated efforts to address these topics in the near future. Anti-tobacco legislation and education campaigns should be continued and intensified, particularly focusing on the younger population. Programs to increase public awareness on lung cancer, stimulate smoking cessation, shorten the time to diagnosis, and improve access to specialized health care facilities are among the most relevant needs to tackle lung cancer and improve therapeutic results.
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[^1]: NSCLC: non-small cell lung cancer cases; SCC: squamous cell carcinoma cases; Ad: adenocarcinoma cases; and III-IV: patients in stages III or IV. ^a^Studies including only NSCLC cases.

[^2]: NS: never smoker; non-SCC: non-squamous cell carcinoma; and NR: not reported.

[^3]: PS: Eastern Cooperative Oncology Group performance status score; mOS: median overall survival; Re: retrospective; Pro: prospective; NA: not available; NR: not reached; and TKI: tyrosine kinase inhibitor. ^a^Karnofsky performance status ≤ 70%. ^b^Survival for single-agent and doublet-agent arms, respectively. ^c^Survival for bevacizumab-based and pemetrexed-based protocols, respectively. ^d^Only elderly patients (≥ 70 years of age) were included.

[^4]: Survival not reached after a median follow-up of 14 months. ^f^Survival among patients receiving an EGFR TKI as first- or second-line treatment, respectively.
